Subscribe
Abstract: Failure to recognize heparin-induced thrombocytopenia (HIT) can lead to devastating thrombotic events, including pulmonary embolism and stroke. In most cases, the problem develops within 5 to 14 days after a first-time exposure to heparin. HIT can occur with either unfractionated heparin or low molecular weight heparin (LMWH), but the incidence is much lower with LMWH. When HIT is suspected clinically, a functional assay and immunoassay should be performed. However, treatment should not be delayed while waiting for laboratory confirmation. All forms of heparin should be eliminated, and treatment with an alternative anticoagulant should be initiated to prevent new thromboembolic events. Argatroban and lepirudin are the direct thrombin inhibitors that have been approved for the treatment of HIT. Because of the risk of warfarin-induced venous limb gangrene or skin necrosis, warfarin should be avoided in patients with acute HIT until their platelet counts have recovered and they are improving clinically. (J Respir Dis. 2006;27(6):248-259)
Of Bites and the (Little) Hands That Feed
Green Nail Syndrome
Allergic Reactions: Allergic Purpura
Nummular Eczema and Fixed Drug Eruption
Girish Kunapareddy, MD; Sara M. Tolaney, MD, MPH
June 15, 2026
Marla D. Lipsyc-Sharf, MD; Richard Zelkowitz, MD
June 17-19, 2026
Seth A. Wander, MD, PhD; Kate Baxstrom, MD
Richard Bedlack, MD, PhD
June 23, 2026
1 Session is Available!
Terry Heiman-Patterson, MD
Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA
Selina R. McGee, OD, FAAO
Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD
John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; John Hovanesian, MD, FACS
Seth A. Wander, MD, PhD; Yang Liu, MD
Yelda Nouri, MD; Sara Nunnery, MD, MSCI
July 10-11, 2026
Rachel N. Grisham, MD; Ramez N. Eskander, MD; Oladapo Yeku, MD, PhD